Introduction {#sec1-1}
============

Obesity has become one of the most important public health problems in the world, with a growing prevalence in both developed and developing countries. This epidemic can be attributed to the modern lifestyle characterized by lack of physical activity and consumption of diets rich in fat.\[[@ref1]\]

Since metabolic syndrome is strongly linked to obesity, the continuing rise in the prevalence of obesity is closely followed by increased rates of metabolic syndrome. Prevalence of metabolic syndrome ranges from 11% to 41% in India. While studies show a high prevalence of metabolic syndrome in Asian Indians, truly representative data from all regions of India are not available.\[[@ref2]\]

Obstructive sleep apnea (OSA) is a clinical condition characterized by recurrent episodes of complete obstruction (apnea) or partial obstruction (hypopnea) of the upper airway, leading to increased negative intrathoracic pressure, sleep fragmentation, and intermittent hypoxia during sleep. OSA afflicts all age groups. Its severity is usually graded according to the average number of apneic and hypopneic episodes per sleep hour (apnea--hypopnea index \[AHI\]) in sleep studies.\[[@ref3]\] Research on the current prevalence of OSA indicated that one-third of sleep studies showed some degree of OSA (AHI ≥ 5). Among adults aged 30 -- 70 years, approximately 13% of men and 6% of women have moderate-to-severe forms of OSA (AHI ≥ 15).\[[@ref4]\]

Obesity is a major risk factor for OSA because it promotes enlargement of soft tissue structures within and surrounding the airway, thereby contributing significantly to pharyngeal airway narrowing.\[[@ref5][@ref6]\] In 1998, Wilcox *et al*. proposed the name "syndrome Z" for the combination of metabolic syndrome (syndrome X) and OSA to reflect the close association of components of metabolic syndrome with OSA.\[[@ref7]\]

OSA also promotes metabolic dysfunction and increases the incidence of metabolic syndrome overall, as well as its individual components. Therefore, OSA seems to be more than an epiphenomenon in the metabolic syndrome. Early treatment of OSA in patients with metabolic syndrome has produced some beneficial effects on individual components of metabolic syndrome; hence, early identification and treatment of OSA in patients with metabolic syndrome is essential.

Although the incidence of metabolic syndrome in India is on the rise, there is a paucity of Indian data on its correlation with OSA. This study was undertaken to find out the prevalence of OSA in patients with metabolic syndrome and to highlight the importance of evaluating metabolic syndrome patients for OSA. The vicious nature of the combination of metabolic syndrome and OSA calls for urgent participation of physicians at all levels, especially primary care physicians to promote healthy lifestyle so as to curb the epidemic of obesity and thereby reduce the incidence of OSA. Primary care physicians also have a role in identifying OSA early in the patients of metabolic syndrome as early identification and treatment of OSA may produce beneficial effects on individual components of metabolic syndrome and may have significant cardiovascular benefit.

Methods {#sec1-2}
=======

This cross-sectional analytical study, conducted in the department of Medicine of a tertiary care teaching hospital, enrolled 100 patients. Fifty patients with metabolic syndrome were taken as cases and 50 patients without metabolic syndrome formed the control group.

Inclusion criteria {#sec2-1}
------------------

1\. For Cases

Patients of any gender above 30 and below 60 years of age, who gave informed consent, and who fulfilled the 2005 International Diabetes Federation (IDF) criteria\[[@ref8]\] for metabolic syndrome, were included in this study.

According to the 2005 IDF criteria, metabolic syndrome is diagnosed in a patient having:

(1)central obesity (waist circumference \[WC\] ≥ 90 cm in males and ≥ 80 cm in females)(2)with any two of the following:- Serum triglycerides (TG) ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for lipid abnormality.- Serum HDL cholesterol (HDL-c) \< 40 mg/dL (1 mmol/L) in males and \< 50 mg/dL (1.3 mmol/L) in females, or specific treatment for lipid abnormality.- Blood pressure (BP) in supine position (after 10 min rest): systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg, or on the treatment of previously diagnosed hypertension.- Fasting blood sugar (FBS) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes mellitus.

2\. For Controls

Patients of any gender above 30 and below 60 years of age, who gave informed consent, and who did not have metabolic syndrome, were included as controls.

Exclusion criteria {#sec2-2}
------------------

Patients below 30 and above 60 years of age, those with chronic respiratory problems, congestive heart failure, cognitive impairment, history of cerebrovascular accident within the preceding 30 days, and those on sedatives, antipsychotics, or antiobesity drugs were excluded.

**Data collection procedure**: The study conformed to the Helsinki Declaration. Approval was sought from the institutional ethics committee. All the participants were explained about the purpose of the study and were ensured strict confidentiality. Then, written informed consent was taken from each of them before their enrolment for the study. After a detailed history and thorough clinical examination, all subjects (50 cases and 50 controls) underwent overnight polysomnography (sleep study). The sleep study was carried out using the machine "SleepCare" which works with the software "SleepCare 1.0.3." In a sleep study, the following parameters were used to assess the sleep stages:

\- Electroencephalography

\- Electrooculography

\- Surface electromyography of limb muscles (to detect limb movements, periodic or other)

In addition, other parameters, including nasal airflow (for evaluation of apneas and hypopneas), electrocardiography, pulse oximetry, respiratory effort (thoracic and abdominal), and sound recordings to measure snoring, were also monitored.

The following respiratory events were noted: hypopnea, obstructive apnea, mixed apnea, and central apnea. The definitions of these events are incorporated in the "SleepCare" software. The number of respiratory events (obstructive apnea and hypopnea) per hour of sleep, called the AHI or respiratory disturbance index, was calculated. This index was used to grade the severity of OSA, as follows: no OSA (AHI \<5 events/h), mild OSA (AHI ≥ 5 but \< 15 events/h), moderate OSA (AHI ≥ 15 but \< 30 events/h), and severe OSA (AHI ≥30 events/h).

The proportion of OSA in the two study groups was determined and the significance of the difference in the proportion of OSA between these two groups was assessed using the Chi-square test. The mean AHIs in the two study groups were compared using the Student *t*-test.

The subjects were also divided into subgroups according to the severity of OSA ("no OSA," mild OSA, moderate OSA, and severe OSA). The mean level of each of the metabolic syndrome parameters (FBS, systolic BP, diastolic BP, serum TG, serum HDL) was determined in each of these subgroups; comparisons between these subgroups were then made using the ANOVA *F*-test.

Results {#sec1-3}
=======

In this study, 100 subjects were included; of these, 69 were males and 31 were females. Out of 50 cases with metabolic syndrome, 35 (70%) were males and 15 (30%) were females. Among 50 controls without metabolic syndrome, 34 (68%) were males and 16 (32%) were females. Therefore, gender-wise distribution in metabolic syndrome and nonmetabolic syndrome subject groups were comparable.

Among cases, 15 (30%) belonged to the age group 30 -- 40 years, 18 (36%) were in the age group 40 -- 50 years, and 17 (34%) were aged between 50 and 60 years. Among controls, 14 (28%) were in the age group 30 -- 40 years, 20 (40%) belonged to the age group 40 -- 50 years, and 16 (32%) were aged between 50 and 60 years. The mean age of the case group was 45.56 (±7.048) years, while that of the control group was 45.00 (±6.839) years. Therefore, both groups were age-matched.

The mean WC values in the case and control groups were 102.94 cm (±8.110) and 81.64 cm (±5.424), respectively. The mean systolic and diastolic BPs in the case group were 146.36 mmHg (±16.614) and 91.12 mmHg (±7.742), respectively, while in the control group, these were 137.68 mmHg (±8.460) and 82.88 mmHg (±7.386), respectively. The mean FBS levels in the case and control groups were 127 mg/dL (±34.118) and 95.52 mg/dL (±18.339), respectively. The mean serum TG and HDL levels in the case group were 166.36 mg/dL (±19.940) and 47.54 mg/dL (±6.538), respectively and in the control group were 142.30 mg/dL (±20.629) and 49.64 mg/dL (±5.005), respectively.

Out of the 50 cases, 33 (66%) were found to have OSA, while among the 50 controls, only 6 (12%) had OSA \[[Figure 1](#F1){ref-type="fig"}\]. This difference was statistically significant (*P* \< 0.001).

![Proportion of OSA in metabolic syndrome (case) and nonmetabolic syndrome (control) groups](JFMPC-8-1580-g001){#F1}

Overall, 61 (61%) subjects did not have OSA ("no OSA"), 10 (10%) had mild OSA, 14 (14%) had moderate OSA, and 15 (15%) had severe OSA. Among cases, 17 (34%) were found to have "no OSA," 8 (16%) had mild OSA, 11 (22%) had moderate OSA, and 14 (28%) had severe OSA. Out of the 50 controls, 44 (88%) had "no OSA," 2 (4%) had mild OSA, 3 (6%) had moderate OSA, and only 1 (2%) was found to have severe OSA. These differences were statistically significant (*P* \< 0.001) \[[Figure 2](#F2){ref-type="fig"}\].

![Proportion of "no OSA," mild OSA, moderate OSA, and severe OSA in metabolic syndrome (case) and nonmetabolic syndrome (control) groups](JFMPC-8-1580-g002){#F2}

The mean AHI on polysomnography in cases was 18.394 (±14.7957) events/h, whereas in controls, it was 4.970 (±5.7826) events/h; the difference was statistically significant (*P* \< 0.001).

Among 35 males with metabolic syndrome, 12 (34.3%), 5 (14.3%), 8 (22.9%), and 10 (28.6%) had "no OSA," mild OSA, moderate OSA, and severe OSA, respectively. Out of 15 females with metabolic syndrome, 5 (33.3%), 3 (20%), 3 (20%), and 4 (26.7%) were found to have "no OSA," mild OSA, moderate OSA, and severe OSA, respectively. These differences were not statistically significant (*P* = 0.966). Among 34 males without metabolic syndrome, 29 (85.3%), 1 (2.9%), 3 (8.8%), and 1 (2.9%) had "no OSA," mild OSA, moderate OSA, and severe OSA, respectively. Out of 16 females without metabolic syndrome, 15 (93.8%) were found to have no OSA, 1 (6.2%) had mild OSA, and none (0%) had moderate and severe OSA. These differences were also not statistically significant (*P* = 0.519).

The mean WC values in the "no OSA," mild OSA, moderate OSA, and severe OSA groups were 85.61 cm (±9.592), 101.2 cm (±9.784), 101.86 cm (±10.369), and 104.6 cm (±9.077), respectively; these differences were statistically significant (*P* \< 0.001) \[[Table 1](#T1){ref-type="table"}\].

###### 

Mean WC in "no OSA," mild OSA, moderate OSA, and severe OSA groups

  -------------------------------------------------------------------------
  Variable   OSA severity   *n*      Mean     Std. deviation   *F*
  ---------- -------------- -------- -------- ---------------- ------------
  WC         No OSA         61       85.61    9.592            25.336\
                                                               *P*\<0.001

  Mild       10             101.20   9.784                     

  Moderate   14             101.86   10.369                    

  Severe     15             104.60   9.077                     

  Total      100            92.29    12.715                    
  -------------------------------------------------------------------------

The mean FBS levels in the "no OSA," mild OSA, moderate OSA, and severe OSA groups were 99.16 mg/dL (±20.434), 117.5 mg/dL (±29.179), 124.5 mg/dL (±33.112), and 143.93 mg/dL (±41.008), respectively; these differences were statistically significant (*P* \< 0.001) \[[Table 2](#T2){ref-type="table"}\].

###### 

Mean FBS level in "no OSA," mild OSA, moderate OSA, and severe OSA groups

  -------------------------------------------------------------------------
  Variable   OSA severity   *n*      Mean     Std. deviation   *F*
  ---------- -------------- -------- -------- ---------------- ------------
  FBS        No OSA         61       99.16    20.434           12.608\
                                                               *P*\<0.001

  Mild       10             117.50   29.179                    

  Moderate   14             124.50   33.112                    

  Severe     15             143.93   41.008                    

  Total      100            111.26   31.510                    
  -------------------------------------------------------------------------

The mean systolic BP measurements in the "no OSA," mild OSA, moderate OSA, and severe OSA groups were 138.49 mmHg (±10.518), 142.4 mmHg (±12.322), 145.71 mmHg (±13.379), and 152.67 mmHg (±20.587), respectively; these differences were statistically significant (*P* = 0.002). The mean diastolic BP measurements in the "no OSA," mild OSA, moderate OSA, and severe OSA groups were 84.2 mmHg (±7.552), 88 mmHg (±6.928), 90.86 mmHg (±7.048), and 94.13 mmHg (±9.812), respectively; these differences were also statistically significant (*P* \< 0.001).

The mean serum TG levels in the "no OSA," mild OSA, moderate OSA, and severe OSA groups were 146.05 mg/dL (±21.214), 157.20 mg/dL (±19.792), 165.43 mg/dL (±20.706), and 175.73 mg/dL (±20.436), respectively; these differences were statistically significant (*P* \< 0.001) \[[Table 3](#T3){ref-type="table"}\].

###### 

Mean serum TG levels in "no OSA," mild OSA, moderate OSA, and severe OSA groups

  -------------------------------------------------------------------------
  Variable   OSA severity   *n*      Mean     Std. deviation   *F*
  ---------- -------------- -------- -------- ---------------- ------------
  Serum TG   No OSA         61       146.05   21.214           9.812\
                                                               *P*\<0.001

  Mild       10             157.20   19.792                    

  Moderate   14             165.43   20.706                    

  Severe     15             175.73   20.436                    

  Total      100            154.33   23.529                    
  -------------------------------------------------------------------------

The mean serum HDL levels in the "no OSA," mild OSA, moderate OSA, and severe OSA groups were 50.39 mg/dL (±5.336), 47.1 mg/dL (±6.350), 47.07 mg/dL (±4.565), and 43.67 mg/dL (±5.815), respectively; these differences were statistically significant (*P* \< 0.001) \[[Table 4](#T4){ref-type="table"}\].

###### 

Mean serum HDL levels in "no OSA," mild OSA, moderate OSA, and severe OSA groups

  ------------------------------------------------------------------------
  Variable    OSA severity   *n*     Mean    Std. deviation   *F*
  ----------- -------------- ------- ------- ---------------- ------------
  Serum HDL   No OSA         61      50.39   5.336            7.006\
                                                              *P*\<0.001

  Mild        10             47.10   6.350                    

  Moderate    14             47.07   4.565                    

  Severe      15             43.67   5.815                    

  Total       100            48.59   5.888                    
  ------------------------------------------------------------------------

Discussion {#sec1-4}
==========

This study explored the association between metabolic syndrome and OSA. So far, various studies have focused on determining the prevalence of metabolic syndrome in OSA patients and showing that metabolic syndrome is more prevalent in such patients than in the general population. This study, on the other hand, attempted to examine the reverse association, that is, to determine the prevalence of OSA in patients with metabolic syndrome.

The present study was done on 100 subjects, 50 with and 50 without metabolic syndrome. The prevalence of OSA in patients with metabolic syndrome (66%) was much higher than in controls without metabolic syndrome (12%). Also, the mean AHI in patients with metabolic syndrome was 18.394 events/h, which was significantly higher than that in controls (4.97 events/h). In a similar study conducted in 30 patients with metabolic syndrome, 22 (73.3%) were found to have OSA.\[[@ref9]\] In another study, 24 patients with metabolic syndrome were subjected to polysomnography and the prevalence of OSA in these patients was 95.8%.\[[@ref10]\] Perez *et al*. enrolled 83 female patients with metabolic syndrome, and they also found a high prevalence of syndrome Z (75.8%) in these patients.\[[@ref11]\]

Metabolic syndrome is associated with obesity, which is the most important reversible risk factor for OSA. Obesity promotes enlargement of soft tissue structures within and surrounding the airway, thereby contributing significantly to pharyngeal airway narrowing. An excess of fat deposition is also observed under the mandible and in the tongue, soft palate, and uvula. Obesity also leads to a reduction of lung volumes during sleep (due to a combination of increased abdominal fat mass and recumbent posture), which reduces longitudinal tracheal traction forces and pharyngeal wall tension; this also contributes to pharyngeal airway narrowing. As compared to peripheral obesity, central obesity is associated with a higher amount of fat deposition in the neck; this leads to a more notable narrowing of the upper airway while asleep.\[[@ref12][@ref13]\]

In the present study, there was no significant difference in the prevalence of OSA between males and females with metabolic syndrome.

The present study showed that the mean WC in subjects with mild, moderate, and severe OSA was significantly higher than the mean WC in subjects with "no OSA." In a similar study, the mean WC in patients with OSA (110.95 cm) was also significantly higher than in subjects without OSA (98.12) (*P* = 0.01).\[[@ref9]\] The finding of increased WC in patients with OSA supports the well-known fact that OSA is associated with central obesity.\[[@ref14][@ref15]\]

In this study, the mean FBS in subjects with OSA was higher than that in subjects without OSA; also, as the severity of OSA increased, the mean FBS levels also increased. In a similar study conducted by Dubey *et al*., in which 50 patients with metabolic syndrome were evaluated for OSA, the mean FBS levels in patients with mild, moderate, and severe OSA were 115.4, 110.9, and 143.68 mg/dL, respectively. In this study, a significant correlation was found between uncontrolled blood glucose and the severity of OSA.\[[@ref16]\] In another study, the mean FBS in patients with OSA was 135.45 mg/dL, which was significantly higher than in subjects without OSA (109.37 mg/dL).\[[@ref9]\] Perez *et al*. in their study observed that the mean FBS in subjects without OSA was 99.8 mg/dL, while the mean FBS levels in patients with mild, moderate, and severe OSA were 117.6, 139.7, and 142.3 mg/dL, respectively; the differences were statistically significant (*P* \< 0.001).\[[@ref11]\] Aronsohn *et al*. showed that increasing severity of OSA was associated with poorer glucose control.\[[@ref17]\] Priou *et al*. also observed that increasing OSA severity was associated with higher HbA1c.\[[@ref18]\] In yet another study, the severity of OSA was associated with increased HbA1c level independent of body mass index in Japanese individuals, especially in those without diabetes.\[[@ref19]\]

Thus, increasing severity of OSA is associated with poorer glycemic control. This might be due to the effect of OSA on glucose metabolism. OSA is linked with glucose intolerance and insulin resistance. Thus, reducing the severity of OSA may be an important therapeutic approach to optimize glycemic control in patients having OSA and glucose intolerance.\[[@ref20][@ref21][@ref22]\]

In the present study, the mean systolic and diastolic BPs in patients with OSA were higher than those in subjects without OSA; also, as the severity of OSA increased, the mean systolic and diastolic BPs also increased. In the study by Dubey *et al*., the mean systolic BPs in patients with no OSA, mild, moderate, and severe OSA were 142, 145.2, 147.81, and 153.18 mmHg, respectively; and the mean diastolic BPs in these patients were 88, 91.2, 93.9, and 97.82 mmHg, respectively, reflecting higher values in patients with OSA than in those without OSA.\[[@ref16]\] In another study, the mean systolic BP in patients with OSA was 146.81 mmHg, which was significantly higher than in patients without OSA (125 mmHg).\[[@ref9]\] Similar results were found in studies conducted by Perez *et al*.\[[@ref11]\] and Walia *et al*.\[[@ref23]\], suggesting a strong association between severe OSA and resistant elevated BP. Martinez-Garcia *et al*. also found higher uncontrolled systolic BP in severe OSA and noted that patients with severe OSA had poorer BP control than those without severe OSA.\[[@ref24]\] The above data suggest that increasing severity of OSA is associated with higher and difficult-to-control BP. There are several potential mechanisms to explain this association. Severe OSA may cause endothelial dysfunction, which is primarily driven by OSA-associated intermittent hypoxia; and endothelial dysfunction is thought to contribute to hypertension. Aldosterone excess and increased sympathetic activity might play a role in the relation between severity of OSA and difficult-to-control BP. Therefore, reducing the severity of OSA might help to optimize BP control in patients with severe OSA and refractory hypertension.\[[@ref23][@ref24]\]

This study revealed that the mean serum TG levels in patients with OSA were significantly higher than in subjects without OSA; also, as the severity of OSA increased, the mean serum TG levels increased. Similarly, the mean HDL levels in patients with OSA were lower than in subjects without OSA. These levels showed a downward trend with an increase in the severity of OSA, which was statistically significant. Dubey *et al*. also noted similar findings; the mean serum TG levels in patients with mild, moderate, and severe OSA were 172.6, 180.86, and 214.91 mg/dL, respectively.\[[@ref16]\] In another study, the mean serum TG in patients with OSA was 170.31 mg/dL, which was significantly higher than in subjects without OSA (151.12).\[[@ref9]\] Nadeem *et al*. found that HDL-c levels correlated well with the severity of OSA; as the severity of OSA increased, the levels of HDL-c decreased. Also, the serum TG levels were significantly higher in patients with severe OSA (*P* = 0.0001).\[[@ref25]\]

Hence, the increasing severity of OSA is associated with poorer control of dyslipidemia. This might be due to the effect of OSA on lipid metabolism. Chronic intermittent hypoxia induced by OSA is associated with the generation of sterol regulatory element-binding protein-1 and stearoyl-coenzyme A desaturase-1, peroxidation of lipids, HDL dysfunction, increased total cholesterol level, and sympathetic dysfunction. Altogether, these factors create a proinflammatory milieu responsible for the development of dyslipidemia and propagation of atherosclerosis in OSA.\[[@ref26]\]

A meta-analysis performed in 2016 evaluated the relationship between metabolic syndrome parameters and OSA. Patients with OSA had higher systolic BP, lower HDL, and higher low density lipoprotein (LDL) levels than subjects without OSA. OSA was also found to be associated with increased TG levels and higher FBS. This meta-analysis found that OSA was associated with abnormal levels of multiple parameters that are markers of metabolic syndrome and suggested that OSA broadly affects this disease.\[[@ref27]\]

Thus, the current study suggests that OSA is quite common in patients with metabolic syndrome, which is associated with an increased risk of cardiovascular disease. In addition, the severity of OSA has a strong correlation with all the components of metabolic syndrome.

Strength of the study {#sec2-3}
---------------------

This study highlights the vicious relationship between OSA and metabolic syndrome. There is a high prevalence of OSA in patients with metabolic syndrome and increasing severity of OSA is associated with poorer control of diabetes, hypertension, and dyslipidemia, which are all components of metabolic syndrome. This study emphasizes the urgent need for recognition of the high prevalence of OSA in patients of metabolic syndrome and also reinforces the importance of screening of OSA in these patients.

Limitations of the study {#sec2-4}
------------------------

This was a single-center study with small sample size.

Conclusions {#sec1-5}
===========

OSA is highly prevalent in patients with metabolic syndrome, which is associated with an increased risk of cardiovascular disease. Also, the increasing severity of OSA is associated with poorer control of diabetes, hypertension, and dyslipidemia, which are all components of metabolic syndrome. Poor control of these components, in turn, further increases the risk of cardiovascular disease. Therefore, reducing the severity of OSA (by early diagnosis and treatment) in patients with metabolic syndrome might help to optimize control of blood sugar, BP, and serum lipids, thereby reducing morbidity and mortality. Therefore, the need for screening metabolic syndrome patients for OSA has been reinforced by this study.
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